Related Experiment Video

Updated: Jun 3, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

[Recommendations for hypercholesterolemic children]

Gérald Luc1, Jean-Philippe Girardet, Éric Bruckert

  • 1Nouvelle société française d’athérosclérose. gerald.luc@univ-lille2.fr

Presse Medicale (Paris, France : 1983)
|March 11, 2011
PubMed

Insights

Childhood hypercholesterolemia, particularly familial hypercholesterolemia, elevates the risk of early cardiovascular disease. This article provides screening and management guidelines for pediatric hypercholesterolemia, including dietary and drug therapy recommendations.

Area of Science:

  • Pediatric Cardiology
  • Clinical Genetics
  • Nutritional Science

Context:

  • Childhood hypercholesterolemias pose a significant risk for premature cardiovascular disease.
  • Monogenic, dominantly inherited forms like familial hypercholesterolemia (FH) are particularly concerning.
  • These conditions stem from genetic mutations, notably in the LDL receptor gene.

Purpose:

  • To propose evidence-based recommendations for screening children for hypercholesterolemia.
  • To outline management strategies for pediatric hypercholesterolemia.
  • To provide guidance on dietary interventions and lipid-lowering drug therapy in children.

Summary:

  • This collaborative article from leading French societies offers a framework for identifying and managing hypercholesterolemia in pediatric populations.
  • It details the specific approach for high-risk inherited hypercholesterolemias.
  • Key aspects covered include dietary management and the indications for, and supervision of, pharmacologic lipid-lowering treatments.

Impact:

  • Aims to improve early detection and intervention for pediatric hypercholesterolemia.
  • Seeks to reduce the long-term cardiovascular risk associated with these genetic lipid disorders.
  • Provides clinicians with practical guidelines for managing affected children.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...